Mark is a pharmacist and initially worked for Baxter Healthcare before completion of a PhD in pharmaceutics at TCD on behalf of Elan Corporation. He joined Servier Laboratories in 1997 as a Project Manager and then worked in marketing as Group Product Manager. In 2001 he completed a Diploma in Business Strategy and subsequently founded a number of businesses including Pharmacy Prime, the Heartbeat Trust and Cardio mark. He also holds adjunct positions as Research Director in the Heart Failure Unit at St Vincent’s University Hospital and Senior Lecturer in the School of Medicine and Medical Science in UCD. Mark’s research interests include cardiovascular therapeutics, biomarkers of hypertensive heart disease and telemedicine. He is a named inventor on several licensed patents and has published his research work extensively. He is Co-Chair of the National Pharmacy Reference Group of the pharmacy regulator in Ireland and has been a member of the Expert Advisory Group on Human Medicines of the Irish Medicines Board, the medicines licensing authority in Ireland, since 2007. Mark’s role is to co-lead the R&D programme, further develop and implement Solvotrin Therapeutics’ commercial and marketing strategy, oversee the design and execution of preclinical and clinical trials, develop product acquisition, out-licensing and co-development strategies, position Solvotrin within the target markets and oversee product brand development. Mark is a pharmacist and initially worked for Baxter Healthcare before completion of a PhD in pharmaceutics at TCD on behalf of Elan Corporation. He joined Servier Laboratories in 1997 as a Project Manager and then worked in marketing as Group Product Manager. In 2001 he completed a Diploma in Business Strategy and subsequently founded a number of businesses including Pharmacy Prime, the Heartbeat Trust and Cardio mark. He also holds adjunct positions as Research Director in the Heart Failure Unit at St Vincent’s University Hospital and Senior Lecturer in the School of Medicine and Medical Science in UCD. Mark’s research interests include cardiovascular therapeutics, biomarkers of hypertensive heart disease and telemedicine. He is a named inventor on several licensed patents and has published his research work extensively. He is Co-Chair of the National Pharmacy Reference Group of the pharmacy regulator in Ireland and has been a member of the Expert Advisory Group on Human Medicines of the Irish Medicines Board, the medicines licensing authority in Ireland, since 2007. Mark’s role is to co-lead the R&D programme, further develop and implement Solvotrin Therapeutics’ commercial and marketing strategy, oversee the design and execution of preclinical and clinical trials, develop product acquisition, out-licensing and co-development strategies, position Solvotrin within the target markets and oversee product brand development.

Pharmaceutical industry